Last updated on November 2019

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus.


Brief description of study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus.

 

Detailed Study Description

  • The total duration of the study is up to 182 weeks, consisting of 3 study periods: a ≤6-week screening period, a 52-week double-blind period, and a 124-week extension period.

 

Clinical Study Identifier: TX217844

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.